|
Title
|
|
|
|
Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Objective. To explore the relationship between adiponectin and albuminuria in a large group of overweight and obese nondiabetic individuals after controlling for potential confounders. Material and Methods. Detailed anthropometiy, computed tomography-measured visceral abdominal adipose tissue, 24-h albuminuria, adiponectin and a series of biochemical parameters were assessed. Four hundred forty patients, predominantly of Caucasian origin, were included (80.2% female). A multiple linear regression model was developed, with albuminuria as the dependent variable and potential predictors as independent variables. Results. The mean age was 40 +/- 13 years, the mean body mass index was 35.7 +/- 6.6 kg/m(2), and the median visceral abdominal adipose tissue was 142.4 (92.3-194.0) cm(2). 10.9% of subjects exhibited microalbuminuria. The median adiponectin level was 9.08 (6.23-12.94) mu g/ml, and the median fasting serum glucose level was 83 (77-89) mg/dl. The strongest significant univariate correlations with albuminuria were visceral abdominal adipose tissue (r = 0.258, p < 0.001), adiponectin (r = -0.265, p < 0.001), waist circumference (r = 0.250, p < 0.001), waist-to-hip ratio (r = 0.236, p < 0.001) and high-density lipoprotein cholesterol (r = -0.211, p < 0.001). The multiple linear regression model revealed a significant positive independent correlation between visceral abdominal adipose tissue and albuminuria (r = 0.134, p = 0.033), between fasting glucose levels and albuminuria (r = 0.390, p = 0.029) and between gender and albuminuria (r = 0.107, p = 0.038). A significant independent negative correlation was identified between adiponectin and albuminuria (r = -0.255, p = 0.022). Conclusions. We observed an independent inverse relationship between adiponectin and albuminuria in overweight and obese nondiabetic individuals. Further investigations are needed to confirm this finding and to clarify whether adiponectin is a risk marker or plays a causative role in developing obesity-induced nephropathy. (C) 2013 Elsevier Inc. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Metabolism: clinical and experimental. - New York
| |
|
Publication
|
|
|
|
New York
:
2013
| |
|
ISSN
|
|
|
|
0026-0495
| |
|
DOI
|
|
|
|
10.1016/J.METABOL.2013.05.023
| |
|
Volume/pages
|
|
|
|
62
:11
(2013)
, p. 1570-1576
| |
|
ISI
|
|
|
|
000330924500008
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|